

## TOP-TIER PHARMA TO SHOWCASE APAS® RESULTS

*Commercial potential highlighted by positive APAS® Independence evaluations results*

**Adelaide, Australia, 8 September 2025:** Leaders in AI microbiology automation, Clever Culture Systems Ltd (ASX: CC5) (CCS or the **Company**), is pleased to announce that top-tier global pharmaceutical companies Astra Zeneca, Bristol Myers Squibb and Pfizer will present APAS® Independence data at major industry conferences over the coming months. The presentations will include new evaluation performance data of the APAS® system for both settle plates (90mm) and contact plates (55mm) as well as global validation and roll out strategies for the technology.

### Highlights:

- **Presentations from AstraZeneca, Bristol Myers Squibb and Pfizer**
- **Multiple platforms: Keynote presentations, scientific posters, interactive demonstrations**
- **New large scale study results validate the core technology across an expanded customer set**
- **New data for APAS® contact plates application demonstrates a complete environmental monitoring solution**
- **AstraZeneca case study details benefits of their global rollout of APAS® Independence**

Brent Barnes, CCS CEO & Managing Director said:

*"We remain steadfast in our commercialisation strategy to engage with the largest pharmaceutical companies globally. Our APAS® technology has been selected for presentation by AstraZeneca, Pfizer and Bristol Myers Squibb at multiple industry leading conferences on the global stage. The data being presented by this quorum is extensive and provides a substantial body of evidence demonstrating the technology's performance in real-world customer settings. This critical data is invaluable for other customers looking to adopt APAS® Independence."*

### APAS® technology to gain recognition from industry leaders at upcoming global conferences

CCS confirms that the APAS® Independence technology continues to gain international recognition, as several major pharmaceutical companies have committed to purchase, evaluate, and standardise APAS® Independence globally. These commitments and presentations at international conferences in the US, UK, Germany, and Australia underscore the technology's performance and validation strategies.

These events also showcase the newly launched APAS® contact plate application, positioning APAS® Independence as the only comprehensive solution for environmental monitoring. At these conferences, CCS will provide interactive demonstrations, including the first customer-generated data using the contact plate application. CCS will educate customers on the validation process, supported by extensive customer data.

APAS® Independence remains the only validated end-point reader for environmental monitoring, establishing CCS's leadership. Reinforcing this, Dr Steven Giglio, CCS Scientific Director, will present on responsible AI development and validation in pharmaceutical manufacturing.

Strong engagement from global pharmaceutical companies at these conferences highlights a significant commercial opportunity for APAS® Independence.

### Details of upcoming conferences

**PDA Asia Pacific Aseptic Manufacturing Excellence Conference** in Melbourne, Australia (13-14 October 2025), APAS Independence to be presented as an industry case study (Website: [Visit Here](#)):

- **Case Study:** "Implementation of Automated EM Plate Reader" by Mark Gracie, LTS Manager, **Pfizer**

**Annual PDA Pharmaceutical Microbiology Conference (PDA Micro)** in Washington, DC, USA (27-29 October 2025), APAS® Independence will feature in both podium and poster sessions presented by leading global pharmaceutical companies (Website: [Visit Here](#)):

- **Podium Presentation:** “A Global Approach to New Technology Introduction and Validation: Automated Colony Counting” by Phil Duncanson, PhD, Senior Director, **AstraZeneca**
- **Poster Presentation:** “Evaluating the APAS® Independence System for Automated Microbial Detection in Environmental Monitoring” by Jennifer Hester, Scientist, **Bristol Myers Squibb**

**PharmIG Annual Conference** in Nottingham, UK (19-20 November 2025), where CCS will have a booth presence at the exhibition, followed by hosting a 1-day workshop focussed on APAS® Independence (Website: [Visit Here](#)):

- **APAS® Discovery Day hosted by AstraZeneca** in Macclesfield, UK (20-21 November 2025), where customers will view the APAS® Independence in operation and hear how it’s been brought into routine production operation.

**PharmaLab Conference** in Düsseldorf, Germany (24–26 November 2025), APAS® Independence will be prominently featured across multiple sessions. PharmaLab is recognised as Europe’s leading pharmaceutical microbiology conference, typically attracting up to 600 delegates annually (Website: [Visit Here](#)):

- **Alternative and Rapid Microbiological Methods:** “Environmental Monitoring Plate Reading Using the APAS® Independence” by Juan Diego González Moreno, Senior Scientist Manufacturing Excellence, **Pfizer**
- **Artificial Intelligence in Pharmaceutical Laboratories:** “Responsible AI Development of Alternative Microbiological Methods used for Environmental Monitoring – a Case Study with the APAS® Independence” by Dr Steven Giglio, Chief Scientific Officer, **Clever Culture Systems**

Approved for release by the CCS Board.

– ENDS –

#### About Clever Culture Systems

Clever Culture Systems (CCS) provides intelligent automation solutions to microbiology laboratories. Based in Adelaide, South Australia, the Company has developed a best-in-class technology, the Automated Plate Assessment System (APAS® Independence), using artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading. The product is currently being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates and to clinical laboratories as an in vitro diagnostic for infectious diseases. Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence to clinical customers in the United States and selected countries in Europe.

#### INVESTOR ENQUIRIES

Clever Culture Systems
<b>Brent Barnes</b> Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: <a href="mailto:info@cleverculturesystems.com">info@cleverculturesystems.com</a>